These results suggest that the function of TAMs as primarily immunosuppressive cells might not fully apply to early stage human lung cancer, but it may explain why some PD-L1-positive patients are nonresponsive to PD-L1 therapy. This evidence concerns the gene CD274 and lung carcinoma.